DSIJ Mindshare

Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results!

In an aim to expand their product portfolio, the company is focusing on developing multiple manufacturing sites

Bhavya Rathod 0 413 Article rating: 3.7

They initiated contract manufacturing from three new locations this quarter and with this, they are currently manufacturing at nine locations across India

Multibagger Alert: Fredun Pharmaceuticals jumps 12 per cent in two days post Q3 results; hits fresh 52-week high

Over Q3FY22, the company has commissioned a state of the art warehousing facility totalling 60,000 sq. ft. capacity.

Armaan Madhani 0 4070 Article rating: 4.5

The stock has gained 30.78 per cent and 163.28 per cent over the past one and six months, respectively. 

RSS
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR